ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09 3 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 3 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

04 3 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

04 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

29 2 2024 16:00:33 提供 Nasdaq GlobeNewswire

Arcutis Announces Pricing of $150 Million Public Offering

28 2 2024 22:30:21 提供 Nasdaq GlobeNewswire

Arcutis Announces Proposed Public Offering

28 2 2024 15:10:00 提供 Nasdaq GlobeNewswire

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

28 2 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 2 2024 04:50:12 提供 Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

16 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 2 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

31 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

29 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

22 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

14 1 2024 03:00:00 提供 Nasdaq GlobeNewswire

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

14 1 2024 03:00:00 提供 Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

15 12 2023 16:11:43 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 12 2023 21:00:49 提供 Nasdaq GlobeNewswire

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

29 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

03 11 2023 06:30:00 提供 Nasdaq GlobeNewswire